Study wrapper · #27
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Editor's note
This narrative review in Sports Medicine surveys the pharmacological profiles, regulatory standing, and safety data for eleven peptides marketed to athletes and patients seeking injury recovery — ranging from FDA-approved tesamorelin to unapproved compounds such as BPC-157, TB-500, and MOTS-c. The authors' central finding is that a substantial regulatory gap exists: while some peptides (tesamorelin, sermorelin historically) have cleared rigorous approval processes for specific indications, many others circulate in a gray market supported primarily by animal-model data and amplified by social media.
A narrative review design is worth flagging. Unlike a systematic review or meta-analysis, it does not involve exhaustive literature search protocols or pooled effect-size estimates, which means it reflects editorial judgment about which evidence to emphasise. That is appropriate for a broad landscape survey but limits the precision of any efficacy conclusions.
The key caveat — which the authors acknowledge directly — is that favorable preclinical signals in rodent tissue-repair and metabolic models do not reliably translate to human outcomes. The review also raises an...
Plain-language abstract
This review article, published in Sports Medicine, set out to map what is known — and what is not known — about eleven peptides being used or marketed in sports medicine settings, both those approved by regulators and those sold outside formal regulatory oversight.
The peptides examined include tesamorelin (FDA-approved for fat redistribution in HIV patients), sermorelin (a former FDA-approved drug, now discontinued), CJC-1295, ipamorelin, BPC-157, TB-500, GHK-Cu, AOD-9604, follistatin-344, MOTS-c, and thymosin beta-4. The authors reviewed existing published research on each compound's biological mechanisms, known safety information, and current regulatory status.
The review found that many unapproved peptides show promising results for tissue repair and metabolism in animal studies, but that rigorous human safety data are largely absent. The authors noted that this creates meaningful risk for patients using these compounds outside medical supervision. A parallel gray market has grown up around these products, operating with little regulatory oversight.
The review also highlighted two factors that shape how people perceive peptide benefits beyond any direct biological effect: the placebo effect and social media, which together may amplify expectations and reported outcomes in ways that are difficult to separate from pharmacological action.
The authors propose a framework to help clinicians discuss peptide use with patients and to support evidence-based...